Despite 22% gain today, Codex DNA still well down from June IPO price

Feb. 07, 2022 2:22 PM ETCodex DNA, Inc. (DNAY)PFEBy: Jonathan Block, SA News Editor

Stock Market Rollercoaster

DNY59/iStock via Getty Images

  • Despite double-digit gains today, Codex DNA (DNAY +22.7%) is still down ~38% from its IPO in June 2021.
  • Its IPO was priced at $16. In afternoon trading today, shares stood at $9.33
  • Since the IPO, trading in Codex DNA has been volatile.
  • Last month, Codex benefitted from a deal with Pfizer (PFE +0.7%) to develop mRNA vaccines and biotherapeutics.
  • Seeking Alpha contributor Edmund Ingham called Codex a buy just after the Pfizer deal was announced.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.